Flux Peptides
$0.00 0

Cart

No products in the cart.

Retatrutide

Retatrutide

Price range: $80.00 through $140.00

Retatrutide

Retatrutide (LY3437943) is a synthetic modified peptide of 39 amino acid residues that acts as an agonist at three receptors involved in metabolic regulation: the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon (GCG) receptors. It is an investigational compound and is not an approved medicine in Canada or the United States.

  • Purity: ≥99.0% (HPLC Tested)
  • Receptor Targets: GLP-1, GIP and glucagon (GCG)
  • Format: Lyophilized Powder for Laboratory Research
  • Key Research Focus: Triple incretin receptor signalling in metabolic research
  • Storage: Store at minus 20 degrees Celsius, sealed and protected from light and moisture
SKU: FLX-RETA Category:

Description

Retatrutide Overview

Retatrutide is a synthetic modified peptide that acts as an agonist at three receptors involved in metabolic regulation: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor and the glucagon (GCG) receptor. KEGG DRUG classifies it as a modified peptide and records a chain of 39 amino acid residues.

Retatrutide, also identified as LY3437943, is an investigational compound. It has been evaluated in sponsor-run clinical trials, including the Phase 3 TRIUMPH programme, and it has not been approved as a medicine by Health Canada or the United States Food and Drug Administration. Research interest centres on how the addition of glucagon receptor activity alongside GIP and GLP-1 receptor activity changes measured outcomes such as energy expenditure and hepatic lipid handling, in contrast with single and dual receptor agonists.

Technical Specifications

  • Peptide Name: Retatrutide
  • Synonyms: LY3437943, LY-3437943, GGG tri-agonist, “Triple G”
  • CAS Number: 2381089-83-2
  • Molecular Formula: C221H342N46O68
  • Molar Mass: 4731.34 g/mol (monoisotopic exact mass 4728.47)
  • Chain Length: 39 amino acid residues
  • Purity: ≥99.0% (determined by HPLC)
  • Appearance: White to off-white lyophilized powder
  • Solubility: Soluble in sterile water or bacteriostatic water

Mechanism of Action (Research Context)
Retatrutide has been studied as a single molecule that engages three receptor pathways. Findings below come from published preclinical and clinical trial reports rather than from testing of this product:

  • GLP-1 Receptor Agonism: Studied in relation to glucose-dependent insulin secretion and the rate of gastric emptying.
  • GIP Receptor Agonism: Studied in relation to insulin sensitivity and lipid handling in adipose tissue.
  • Glucagon (GCG) Receptor Agonism: The feature that distinguishes retatrutide from dual GIP and GLP-1 agonists. Glucagon receptor activity has been examined in research settings for its association with energy expenditure and with hepatic lipid metabolism.

Storage and Handling

  • Lyophilized (Powder): Store at minus 20 degrees Celsius, sealed and protected from light and moisture; see the batch documentation for the retest date. Avoid repeated freeze and thaw cycles.
  • In Solution: Once dissolved in a research solvent, keep the solution at 4 degrees Celsius and protected from light, and treat it as suitable for experimental work for up to 21 days.
  • Handling: Standard laboratory safety practice applies. Wear protective gloves and eyewear.

Testing and Quality Control
Every batch of Retatrutide is checked by:

  1. HPLC (High-Performance Liquid Chromatography): to confirm the purity profile against the ≥99.0% specification.
  2. MS (Mass Spectrometry): to confirm the molecular weight and the identity of the 39 residue peptide.

For laboratory research use only. Not for human or veterinary use.

Further reading

Additional information

Size

10mg, 20mg